Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial

Renal Cell ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.4565 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 4565-4565 ◽

Cited By ~ 5

Author(s):

Ai-Ping Zhou ◽

Jianhui Ma ◽

Yuxian Bai ◽

Yan Song ◽

Hangzhong Li ◽

...

Keyword(s):

Clinical Trial ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Commentary on Randomized phase II trial of first-line treatment with sorafenib vs. interferonα-2a in patients with metastatic renal cell carcinoma

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2009.07.007 ◽

2009 ◽

Vol 27 (5) ◽

pp. 572

Author(s):

Donald L. Trump

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Randomized phase II study of sunitinib + CXCR4 inhibitor LY2510924 versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.4547 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 4547-4547 ◽

Cited By ~ 1

Author(s):

John D. Hainsworth ◽

Joseph Ronald Mace ◽

James Andrew Reeves ◽

Edward J. Crane ◽

Oday Hamid ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.2105 ◽

2021 ◽

Vol 32 ◽

pp. S1304-S1305

Author(s):

N.S. Vasudev ◽

G. Ainsworth ◽

S. Brown ◽

L. Pickering ◽

T.S. Waddell ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Trial ◽

Advanced Renal Cell Carcinoma ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

Annals of Oncology ◽

10.1093/annonc/mdy283.140 ◽

2018 ◽

Vol 29 ◽

pp. viii331

Author(s):

F. Collinson ◽

S. Brown ◽

H. Buckley ◽

G. Ainsworth ◽

H. Howard ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

7122 Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma (mRCC): preliminary results

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71455-7 ◽

2009 ◽

Vol 7 (2) ◽

pp. 429-430 ◽

Cited By ~ 4

Author(s):

C.H. Barrios ◽

D. Hernandez-Barajas ◽

M.P. Brown ◽

S.H. Lee ◽

L. Fein ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Once Daily ◽

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma

Cancer ◽

10.1002/cncr.26440 ◽

2011 ◽

Vol 118 (5) ◽

pp. 1252-1259 ◽

Cited By ~ 67

Author(s):

Carlos H. Barrios ◽

David Hernandez-Barajas ◽

Michael P. Brown ◽

Se-Hoon Lee ◽

Luis Fein ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Once Daily ◽

Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

Yearbook of Urology ◽

10.1016/s0084-4071(09)79341-8 ◽

2009 ◽

Vol 2009 ◽

pp. 104-106

Author(s):

D.E. Coplen

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Trial ◽

Interferon Alfa ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Faculty Opinions recommendation of Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1157292.617430 ◽

2009 ◽

Author(s):

David M Nanus

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Trial ◽

Interferon Alfa ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma

European Urology ◽

10.1016/j.eururo.2021.03.016 ◽

2021 ◽

Author(s):

Irbaz Bin Riaz ◽

Huan He ◽

Alexander J. Ryu ◽

Rabbia Siddiqi ◽

Syed Arsalan Ahmed Naqvi ◽

...

Keyword(s):

Systematic Review ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Meta Analysis ◽

Line Treatment ◽

First Line ◽